Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.